Bipolar Disorder
📧 Sign up to get email alerts when something new happens for Bipolar Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-09-02Clinical Trial Update: Brain Stimulation and Cognitive Training [NA]
A completed clinical trial from University of Michigan evaluating brain stimulation and cognitive training for bipolar disorder and schizoaf…
-
FDA approval · 2020-08-31FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for Lamictal (lamotrigine) submitted by GlaxoSmithKline LLC.
-
FDA label_change · 2020-08-31FDA Approved: LAMICTAL ODT — Supplemental Application (GlaxoSmithKline LLC)
FDA supplemental application approval for LAMICTAL ODT (lamotrigine) by GlaxoSmithKline, seeking changes to the product labeling.
-
FDA label_change · 2020-08-31FDA Approved: LAMICTAL XR — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for Lamictal XR (lamotrigine) submitted by GlaxoSmithKline LLC, resulting in changes to the product …
-
FDA label_change · 2020-08-31FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)
The FDA approved a supplemental application for Lamictal (lamotrigine) from GlaxoSmithKline, updating the product labeling.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-08-19FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for Lamictal (lamotrigine) from GlaxoSmithKline.
-
FDA approval · 2020-08-19FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for Lamictal (lamotrigine) filed by GlaxoSmithKline LLC.
-
FDA approval · 2020-08-19FDA Approved: LAMICTAL ODT — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for Lamictal ODT (lamotrigine) from GlaxoSmithKline LLC, adding or updating the orally disintegratin…
-
CLINICAL_TRIALS trial_result · 2020-08-17Clinical Trial Update: A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder. [Phase 3]
Phase 3 trial evaluating the safety and tolerability of brexpiprazole in adults with Bipolar I Disorder and acute mania has completed with r…
-
CLINICAL_TRIALS trial_result · 2020-08-14Clinical Trial Update: Sequential Multiple Assignment Treatment for Bipolar Disorder [Phase 4]
Phase 4 clinical trial update on sequential multiple assignment treatment for bipolar disorder (bipolar I and II) completed with results pos…
-
EMA approval · 2020-07-31EMA Authorised: Olazax (olanzapine) — Glenmark Pharmaceuticals s.r.o.
Olazax (olanzapine) has been authorised for schizophrenia and bipolar disorder in the European Union.
-
CLINICAL_TRIALS trial_result · 2020-07-20Clinical Trial Update: Ondansetron for Bipolar Disorder and Alcohol Use Disorders [Phase 4]
Phase 4 trial update of ondansetron for bipolar disorder and alcohol use disorders; study completed with posted results.
-
FDA approval · 2020-07-13FDA Approved: LITHIUM CARBONATE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for Lithium Carbonate by Rising Pharma Holdings, Inc., updating the approved labeling/indication fra…
-
CLINICAL_TRIALS trial_result · 2020-07-10Clinical Trial Update: Gao NARASD Lithium Study [Phase 4]
Phase 4 clinical trial update for a lithium study in bipolar disorder; study terminated with results posted.
-
CLINICAL_TRIALS research · 2020-07-09Clinical Trial Update: Modeling Mood Course to Detect Markers of Effective Adaptive Interventions [NA]
A completed clinical trial update focusing on modeling mood course to detect markers of effective adaptive interventions for bipolar disorde…
-
FDA label_change · 2020-07-06FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for divalproex sodium from Zydus Pharmaceuticals USA Inc. to update the product labeling.
-
CLINICAL_TRIALS trial_result · 2020-07-01Clinical Trial Update: Depression, Obesity and Inflammatory Markers [NA]
Clinical trial update from NCT02765100 featuring bipolar disorder, depression, and obesity with completed status and posted results.
-
CLINICAL_TRIALS trial_result · 2020-06-18Clinical Trial Update: DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole [Phase 4]
Phase 4 clinical trial update for a digital medicine study in adults using aripiprazole for schizophrenia, major depressive disorder, or bip…
-
EMA approval · 2020-06-16EMA Authorised: Olazax Disperzi (olanzapine) — Glenmark Pharmaceuticals s.r.o.
Authorised olazax disperzi (olanzapine) for schizophrenia and bipolar disorder in the EU.
-
CLINICAL_TRIALS trial_result · 2020-06-11Clinical Trial Update: Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD [Phase 4]
Phase 4 clinical trial evaluating quetiapine XR with divalproex ER for anxiety symptoms in bipolar disorder patients with panic disorder and…
-
FDA approval · 2020-06-09FDA Approved: LAMOTRIGINE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Lamotrigine from Amneal Pharmaceuticals LLC, authorizing a new generic lamotrigine product.
-
CLINICAL_TRIALS trial_result · 2020-06-04Clinical Trial Update: A Randomized Controlled Trial of Cognitive Remediation and D-cycloserine for Individuals With Bipolar Disorder [Phase 3]
Phase 3 randomized trial evaluating cognitive remediation with D-cycloserine for individuals with bipolar disorder completed, with results p…
-
FDA approval · 2020-05-19FDA Approved: DEPAKOTE SPRINKLES — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for Depakote Sprinkles (divalproex sodium) from AbbVie, updating labeling/indications for the pr…
-
FDA approval · 2020-05-19FDA Approved: DEPAKOTE ER — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for Depakote ER (divalproex sodium) submitted by AbbVie.
-
FDA approval · 2020-04-24FDA Approved: CARBAMAZEPINE — Original Application (Rising Pharma Holdings, Inc.)
The FDA approved Rising Pharma's original application for carbamazepine, a generic anticonvulsant used to treat epilepsy, trigeminal neuralg…